Phys Vivas · endocrine
Multiple Endocrine Neoplasia — Viva Defence
DCE viva defence for Multiple Endocrine Neoplasia.
On this page & tools
Target exams
Multiple Endocrine Neoplasia Viva
Long Case Viva Defence
Opening statement
"This patient presents with a problem best framed as Multiple Endocrine Neoplasia. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]
Examiner questions
Q1: "What makes this urgent?" [1]
"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]
Q2: "What is your first investigation package?" [2]
"I order tests that change management now, not a scattergun panel." [1] [2]
Q3: "Walk me through treatment." [1]
"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]
Q4: "What is the classic trap?" [2]
"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]
Short case
Counsel the patient on the plan, risks and warning symptoms in plain language. [1] [2]
References
- [1]Thelen AE, Hogan EM, Su MW, McHenry CR The Genetics of Familial Neoplastic Thyroid Disease and Primary Hyperparathyroidism Surg Clin North Am, 2026.PMID 42419309
- [2]Noso S, Miki H, Hiromine Y, Babaya N, et al. Metachronous multiple insulinomas in oculo-facio-cardio-dental syndrome harboring a novel BCOR deletion: a case report with review of literature Endocr J, 2026.PMID 42324136
- [3]Nosé V, Canberk S, Baloch Z Recognizing Familial Thyroid Neoplasia: The Pathologist's Role in Diagnosis and Management Adv Anat Pathol, 2026.PMID 42319956
- [4]Pawlak KM, Jagielski M, Papanikolaou IS, Hong W, et al. Pancreatic cystic lesions in hereditary syndromes: Diagnostic role of endoscopic ultrasound Best Pract Res Clin Gastroenterol, 2026.PMID 42167859
- [5]Mariën L, Chhajlani S, De Herdt C, Ceulemans K, et al. Germline MEN1 testing patterns in patients with neuroendocrine tumors: A 12-year retrospective analysis within NETwerk, an ENETS center of excellence J Neuroendocrinol, 2026.PMID 42140697
- [6]Moura MJ, Chatterjee A, Wali S, Garza DR, et al. Refractory immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy: a multiorgan management review Expert Opin Drug Saf, 2026.PMID 41995025
- [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
- [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922